Celularity Celularity
  • Home
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisors
    • Manufacturing
    • Biobanking
    • Tour Our Facility
    • Expanded Access Policy
  • Science
    • Power of Placenta
    • NK Cell Platform
    • T Cell Platform
    • Exosomes
    • Advanced Biomaterials
  • Pipeline
  • Newsroom
  • Investors
    • Investor Relations
    • SEC Filings
    • Corporate Governance
  • Careers
Celularity
MENU

Harnessing the power of the placenta

Celularity’s unique technology realizes the full promise of cell therapies by harnessing the immunomodulatory and regenerative properties of the postpartum placenta.

Years of Research

Into the biological activities of placental-derived cells

Pioneering Technology Platform

To harness the power of multiple placental-derived cell types

Significant unmet Global Need

For inventory-ready, off-the-shelf allogeneic therapies

The Time has arrived

For cellular medicine to be available for everyone

Our Technology

Why use postpartum placental-derived cells?

One of the biggest challenges cell therapy developers face is the human immune system—how do you make a cell-based treatment that the patient’s immune system does not reject as foreign?

Currently approved treatments overcome this challenge by using the patient’s own cells, autologous cell therapy, an approach that is extremely expensive and difficult to scale.

Our Pipeline

At Celularity, we start with a material that normally possesses a low potential for provoking an immune response, the placenta, to develop allogeneic cell therapies that can be used without the need for matching the patient to the donor.

Then, using our proprietary technology, we convert a plentiful and normally discarded source material into potential therapeutics, with a single placenta capable of yielding 100 – 100,000+ doses, depending on the therapeutic.

Our technology makes it possible to develop cell therapies that are scalable and cost-effective, and that can accelerate preclinical development to as little as 18 – 24 months.

Our Celularity IMPACT™ Platform

Fully Integrated Product Development Cycle

Celularity IMPACT platform

The Process is the Product

Sourcing to manufacture our full suite of products

Placenta stem cell manufacturing process

Best In Class

Highly Scalable Biosourcing and In-house GMP Manufacturing

We obtain ethically-sourced biomaterials through an extensive, established network. Donors and biomaterials are screened and tested to verify the lack of communicable diseases, and then processed in our state-of-the-art, 150,000 square-foot, GMP/ GTP facility.

Because our manufacturing process is highly modular, production is efficient, scalable, and reproducible.

At the hospital

  • Donor enrollment, qualification, selection, and informed consent
  • Biomaterial collection and testing

At our manufacturing facility

  • Proprietary cell harvesting and processing
  • Master cell bank establishment
  • Advanced cell manufacturing

Interested in joining the Celularity team of scientists, clinicians, and operators?

Career Opportunities
Celularity_Nasdaq_CELU-1

Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Company

  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers

Science

  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing

Investors

  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2025. All rights reserved.     Privacy Policy     Terms & Conditions

Company
  • About
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Tour Our Facility
  • Careers
Science
  • Pipeline
  • NK Cell Platform
  • T Cell Platform
  • Lifebank
  • Advanced Biomaterials
  • Manufacturing
Investors
  • Investor Relations
  • Partnerships
  • SEC Filings
  • Corporate Governance
  • Press Releases

Celularity Inc. © 2024. All rights reserved.
Privacy Policy     Terms & Conditions